生物制剂时代的重度 T2 高哮喘：欧洲专家意见。

Severe T2-high asthma in the biologics era: European experts' opinion.

机构信息

Nuffield Dept of Medicine and Oxford Respiratory NIHR BRC, University of Oxford, Oxford, UK.

Dept of Internal Medicine, University Hospital Schleswig-Holstein, Kiel, Germany.

出版信息

Eur Respir Rev. 2019 Jul 8;28(152). doi: 10.1183/16000617.0054-2019. Print 2019 Jun 30.

DOI:10.1183/16000617.0054-2019

PMID:31285291

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9489011/

Abstract

The European Respiratory Biologics Forum gathered participants from 21 countries in Madrid, Spain, to discuss the management and treatment of severe asthma in the era of biologics. The current insights on the pathophysiology of severe asthma were discussed, as well as the role of respiratory biologics in clinical practice and strategies for eliminating chronic use of oral corticosteroids. The participants also highlighted the key challenges in identifying patients with severe asthma based on phenotypes, biomarkers and treatable traits, and the existing problems in patient referral to specialist care. The monitoring of treatment was debated and the need for a change towards precision medicine and personalised care was emphasised throughout the meeting. This review provides a summary of the discussions and highlights important concerns identified by the participants regarding the current management of severe asthma.

摘要

欧洲呼吸生物制剂论坛在西班牙马德里召集了来自 21 个国家的参与者，讨论生物制剂时代严重哮喘的管理和治疗。目前对严重哮喘病理生理学的见解，以及呼吸生物制剂在临床实践中的作用和消除慢性口服皮质类固醇使用的策略进行了讨论。与会者还强调了根据表型、生物标志物和可治疗特征识别严重哮喘患者的关键挑战，以及将患者转介至专科护理方面存在的问题。治疗监测也进行了辩论，会议强调需要向精准医学和个性化护理转变。本综述总结了讨论内容，并强调了与会者对严重哮喘当前管理提出的一些重要关注。